Literature DB >> 21116467

Dopamine Release and Uptake Impairments and Behavioral Alterations Observed in Mice that Model Fragile X Mental Retardation Syndrome.

Jenny L Fulks1, Bliss E O'Bryhim, Sara K Wenzel, Stephen C Fowler, Elena Vorontsova, Jonathan W Pinkston, Andrea N Ortiz, Michael A Johnson.   

Abstract

In this study we evaluated the relationship between amphetamine-induced behavioral alterations and dopamine release and uptake characteristics in Fmr1 knockout (Fmr1 KO) mice, which model fragile X syndrome. The behavioral analyses, obtained at millisecond temporal resolution and 2 mm spatial resolution using a force-plate actometer, revealed that Fmr1 KO mice express a lower degree of focused stereotypy compared to wild type (WT) control mice after injection with 10 mg/kg (ip) amphetamine. To identify potentially related neurochemical mechanisms underlying this phenomenon, we measured electrically-evoked dopamine release and uptake using fast-scan cyclic voltammetry at carbon-fiber microelectrodes in striatal brain slices. At 10 weeks of age, dopamine release per pulse, which is dopamine release corrected for differences in uptake, was unchanged. However, at 15 (the age of behavioral testing) and 20 weeks of age, dopamine per pulse and the maximum rate of dopamine uptake was diminished in Fmr1 KO mice compared to WT mice. Dopamine uptake measurements, obtained at different amphetamine concentrations, indicated that dopamine transporters in both genotypes have equal affinities for amphetamine. Moreover, dopamine release measurements from slices treated with quinpirole, a D2-family receptor agonist, rule out enhanced D2 autoreceptor sensitivity as a mechanism of release inhibition. However, dopamine release, uncorrected for uptake and normalized against the corresponding pre-drug release peaks, increased in Fmr1 KO mice, but not in WT mice. Collectively, these data are consistent with a scenario in which a decrease in extracellular dopamine levels in the striatum result in diminished expression of focused stereotypy in Fmr1 KO mice.

Entities:  

Year:  2010        PMID: 21116467      PMCID: PMC2992329          DOI: 10.1021/cn100032f

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  63 in total

1.  Stereotypies and tardive dyskinesia: abnormal movements in autistic children.

Authors:  M Campbell; J J Locascio; M C Choroco; E K Spencer; R P Malone; V Kafantaris; J E Overall
Journal:  Psychopharmacol Bull       Date:  1990

2.  Mildly impaired water maze performance in male Fmr1 knockout mice.

Authors:  R D'Hooge; G Nagels; F Franck; C E Bakker; E Reyniers; K Storm; R F Kooy; B A Oostra; P J Willems; P P De Deyn
Journal:  Neuroscience       Date:  1997-01       Impact factor: 3.590

3.  Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse.

Authors:  Yann S Mineur; Frans Sluyter; Sanne de Wit; Ben A Oostra; Wim E Crusio
Journal:  Hippocampus       Date:  2002       Impact factor: 3.899

4.  Epilepsy and EEG findings in males with fragile X syndrome.

Authors:  S A Musumeci; R J Hagerman; R Ferri; P Bosco; B Dalla Bernardina; C A Tassinari; G B De Sarro; M Elia
Journal:  Epilepsia       Date:  1999-08       Impact factor: 5.864

5.  Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome.

Authors:  Elena D Nosyreva; Kimberly M Huber
Journal:  J Neurophysiol       Date:  2006-02-01       Impact factor: 2.714

6.  Postsynaptic endocannabinoid release is critical to long-term depression in the striatum.

Authors:  G L Gerdeman; J Ronesi; D M Lovinger
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

7.  D-amphetamine and L-5-hydroxytryptophan-induced behaviours in mice with genetically-altered expression of the alpha2C-adrenergic receptor subtype.

Authors:  J Sallinen; A Haapalinna; T Viitamaa; B K Kobilka; M Scheinin
Journal:  Neuroscience       Date:  1998-10       Impact factor: 3.590

8.  Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome.

Authors:  Caitlyn H McNaughton; Jisook Moon; Myla S Strawderman; Kenneth N Maclean; Jeffrey Evans; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2008-04       Impact factor: 1.912

9.  Clozapine and prazosin slow the rhythm of head movements during focused stereotypy induced by d-amphetamine in rats.

Authors:  Stephen C Fowler; Jonathan W Pinkston; Elena Vorontsova
Journal:  Psychopharmacology (Berl)       Date:  2007-02-06       Impact factor: 4.415

10.  Stereotyped and complex motor routines expressed during cocaine self-administration: results from a 24-h binge of unlimited cocaine access in rats.

Authors:  Stephen C Fowler; Herbert E Covington; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2007-02-27       Impact factor: 4.415

View more
  14 in total

Review 1.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

2.  Molecular and genetic analysis of the Drosophila model of fragile X syndrome.

Authors:  Charles R Tessier; Kendal Broadie
Journal:  Results Probl Cell Differ       Date:  2012

3.  Motor function and dopamine release measurements in transgenic Huntington's disease model rats.

Authors:  Andrea N Ortiz; Gregory L Osterhaus; Kelli Lauderdale; Luke Mahoney; Stephen C Fowler; Stephan von Hörsten; Olaf Riess; Michael A Johnson
Journal:  Brain Res       Date:  2012-02-24       Impact factor: 3.252

4.  Head-to-head comparisons of carbon fiber microelectrode coatings for sensitive and selective neurotransmitter detection by voltammetry.

Authors:  Yogesh S Singh; Lauren E Sawarynski; Pasha D Dabiri; Wonwoo R Choi; Anne M Andrews
Journal:  Anal Chem       Date:  2011-08-03       Impact factor: 6.986

Review 5.  Neuroscience and actometry: An example of the benefits of the precise measurement of behavior.

Authors:  Troy J Zarcone
Journal:  Brain Res Bull       Date:  2022-04-25       Impact factor: 3.715

Review 6.  RNA-binding proteins, neural development and the addictions.

Authors:  C D Bryant; N Yazdani
Journal:  Genes Brain Behav       Date:  2016-01       Impact factor: 3.449

7.  Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings.

Authors:  Gabriel S Dichter; Cara A Damiano; John A Allen
Journal:  J Neurodev Disord       Date:  2012-07-06       Impact factor: 4.025

8.  Fragile x syndrome.

Authors:  Yingratana McLennan; Jonathan Polussa; Flora Tassone; Randi Hagerman
Journal:  Curr Genomics       Date:  2011-05       Impact factor: 2.236

9.  Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome.

Authors:  Eric W Fish; Michael C Krouse; Sierra J Stringfield; Jeffrey F Diberto; J Elliott Robinson; C J Malanga
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

Review 10.  Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes.

Authors:  Hansen Wang; Sandipan Pati; Lucas Pozzo-Miller; Laurie C Doering
Journal:  Front Cell Neurosci       Date:  2015-02-26       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.